Sofdra™ (sofpironium) topical gel, 12.45% is now available in the US
Our lead dermatology product, Sofdra, is approved for use by the US Food and Drug Administration (FDA).
Mature pipeline of dermatology and antimicrobial products—including Sofdra, an FDA-approved treatment.
World-class team with extensive dermatology drug development and commercialisation expertise.
Global healthcare innovator, poised to transform the most underserved and lucrative markets.
Here at Botanix, we are at the forefront of dermatological innovation. With a world-class team and significant capital, we are committed to addressing common yet underserved skin diseases and infections.
As an ASX-listed company, we are in a prime position to develop and commercialise groundbreaking treatments across broad markets, all while adhering to the highest clinical standards set by the US FDA.
Check out our latest news
https://botanixpharma.com/wp-content/uploads/BOT-Euroz-Hartleys-Forum-web-image-3.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-12-16 22:46:182024-12-16 22:46:18First Sofdra™ prescriptions as commercialization ramps up
https://botanixpharma.com/wp-content/uploads/BOT_Website.png
736
1104
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-11-19 02:40:082024-11-19 02:40:08Botanix presentation at Bell Potter Healthcare Conference
https://botanixpharma.com/wp-content/uploads/241114-Payer-Coverage.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-11-13 23:08:082024-11-13 23:08:18Botanix adds Payer coverage representing ~65 million commercial lives
https://botanixpharma.com/wp-content/uploads/Copy-of-BOT_website-image-1.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-10-28 03:56:592024-10-28 03:58:15Botanix Releases Quarterly Reports
https://botanixpharma.com/wp-content/uploads/From-The-Helm.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-10-10 21:54:582024-10-10 21:55:00From The Helm | Interview with CEO Dr Howie McKibbon
https://botanixpharma.com/wp-content/uploads/Howie-ausbiz.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-10-07 01:45:042024-10-07 01:45:04Ausbiz | Interview with Howie McKibbon
https://botanixpharma.com/wp-content/uploads/BOT-Euroz-Hartleys-Forum-web-image-2.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-10-02 23:57:062024-10-02 23:57:07Botanix staffing update and AGM Notice of Meeting
https://botanixpharma.com/wp-content/uploads/Conference.png
850
1600
Haley Chartres
/wp-content/uploads/botanix-logo.png
Haley Chartres2024-09-24 00:21:482024-09-24 00:22:39Botanix presentation at leading investor conferences and roadshow
“Compelling Opportunity” | E&P Research Report
May 21, 2024
In new research on Botanix, leading biotech analyst David Nayagam…
Euroz Hartleys Analysis | Commercial Day Webinar
May 13, 2024
Euroz Hartleys’ Seth Lizee reviews the Botanix Commercial…
Video Available | Commercial Day Webinar
May 13, 2024
Video is now available of the Company’s Commercial Day Webinar…
Botanix Included in the All Ordinaries Index
April 5, 2024
Botanix Pharmaceuticals (ASX:BOT) is honoured to announce the…
